Detail
| LncRNA Name | STARD13 |
| Synonyms | STARD13, ARHGAP37, DLC2, GT650, LINC00464 |
| Region | GRCh38_13:33103135-33350630 Sequence |
| Ensembl | ENSG00000133121 |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 M8170/3 |
| Methods | qPCR, RNAi, Western blot, RIP, Luciferase reporter assay etc. |
| Sample | HCC tissues, cell lines (HepG2, Huh7, L02) |
| Expression Pattern | down-regulated |
| Function Description | STARD13 and Fas expression levels were significantly decreased and positively correlated in HCC tissues. Patients with higher STARD13 or Fas expression levels had longer overall survival.Additionally, STARD13 3'-UTR enhanced cellular apoptosis and the 3'-UTRs of STARD13 and Fas were predicted to harbor nine similar miRNA binding sites. And STARD13 3'-UTR promoted Fas expression in a 3'-UTR- and miRNA-dependent way and increased the sensitivity of HCC cells to chemotherapy. |
| Pubmed ID | 27844181 |
| Year | 2017 |
| Title | STARD13 promotes hepatocellular carcinoma apoptosis by acting as a ceRNA for Fas. |
| External Links |
| Links for STARD13 | GenBank HGNC lncrnadb Noncode |
| Links for hepatocellular carcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.